| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Immunotherapy, Adoptive | 15 | 2022 | 254 | 2.340 |
Why?
|
| Melanoma | 26 | 2017 | 482 | 1.910 |
Why?
|
| Receptors, Antigen, T-Cell | 18 | 2022 | 419 | 1.560 |
Why?
|
| Proto-Oncogene Proteins B-raf | 14 | 2017 | 154 | 1.510 |
Why?
|
| T-Lymphocytes | 20 | 2022 | 1277 | 1.370 |
Why?
|
| Cancer Vaccines | 8 | 2025 | 165 | 1.170 |
Why?
|
| Dendritic Cells | 8 | 2014 | 455 | 1.080 |
Why?
|
| CD8-Positive T-Lymphocytes | 16 | 2022 | 624 | 0.910 |
Why?
|
| Sulfonamides | 11 | 2015 | 328 | 0.810 |
Why?
|
| Genetic Therapy | 8 | 2023 | 379 | 0.810 |
Why?
|
| Indoles | 11 | 2015 | 306 | 0.800 |
Why?
|
| Lentivirus | 9 | 2010 | 44 | 0.780 |
Why?
|
| Genetic Vectors | 11 | 2018 | 443 | 0.770 |
Why?
|
| Antigens, Neoplasm | 11 | 2025 | 345 | 0.760 |
Why?
|
| Neoplasms | 11 | 2025 | 3117 | 0.660 |
Why?
|
| Melanoma, Experimental | 7 | 2019 | 111 | 0.590 |
Why?
|
| Cell Line, Tumor | 28 | 2021 | 2669 | 0.570 |
Why?
|
| Skin Neoplasms | 8 | 2015 | 606 | 0.550 |
Why?
|
| Drug Resistance, Neoplasm | 9 | 2017 | 622 | 0.550 |
Why?
|
| Protein Kinase Inhibitors | 11 | 2015 | 598 | 0.530 |
Why?
|
| Transduction, Genetic | 11 | 2018 | 161 | 0.530 |
Why?
|
| MART-1 Antigen | 5 | 2014 | 21 | 0.480 |
Why?
|
| Lymphocytes | 4 | 2014 | 476 | 0.480 |
Why?
|
| Hematologic Neoplasms | 1 | 2019 | 355 | 0.470 |
Why?
|
| Antineoplastic Agents | 13 | 2017 | 2368 | 0.450 |
Why?
|
| Adoptive Transfer | 3 | 2012 | 173 | 0.450 |
Why?
|
| CD4-Positive T-Lymphocytes | 6 | 2019 | 461 | 0.440 |
Why?
|
| Immunotherapy | 8 | 2019 | 725 | 0.420 |
Why?
|
| Mice | 28 | 2022 | 12110 | 0.410 |
Why?
|
| Carbonic Anhydrases | 1 | 2013 | 15 | 0.410 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 5 | 2021 | 149 | 0.390 |
Why?
|
| Antibodies, Monoclonal | 8 | 2015 | 1399 | 0.390 |
Why?
|
| Tumor Microenvironment | 6 | 2022 | 520 | 0.380 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 5 | 2007 | 112 | 0.380 |
Why?
|
| Genetic Engineering | 3 | 2011 | 117 | 0.380 |
Why?
|
| Cell Differentiation | 4 | 2021 | 1592 | 0.370 |
Why?
|
| Antigens, CD | 7 | 2011 | 473 | 0.360 |
Why?
|
| Gelsolin | 5 | 2005 | 11 | 0.360 |
Why?
|
| HLA-A2 Antigen | 2 | 2010 | 30 | 0.360 |
Why?
|
| Lymphocyte Activation | 11 | 2022 | 786 | 0.340 |
Why?
|
| Ovarian Neoplasms | 3 | 2022 | 787 | 0.330 |
Why?
|
| Animals | 33 | 2022 | 28003 | 0.330 |
Why?
|
| Flow Cytometry | 10 | 2012 | 704 | 0.330 |
Why?
|
| Protein Engineering | 1 | 2010 | 146 | 0.310 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2013 | 343 | 0.310 |
Why?
|
| Cytotoxicity, Immunologic | 5 | 2010 | 214 | 0.300 |
Why?
|
| Humans | 65 | 2025 | 92337 | 0.290 |
Why?
|
| Gene Transfer Techniques | 2 | 2010 | 152 | 0.290 |
Why?
|
| Kidney Neoplasms | 1 | 2013 | 530 | 0.280 |
Why?
|
| Mice, Inbred C57BL | 12 | 2019 | 3360 | 0.280 |
Why?
|
| Disease Models, Animal | 3 | 2014 | 2448 | 0.280 |
Why?
|
| Immune Tolerance | 1 | 2010 | 359 | 0.270 |
Why?
|
| Mice, Transgenic | 7 | 2021 | 1589 | 0.260 |
Why?
|
| Neoplasm Proteins | 6 | 2010 | 547 | 0.260 |
Why?
|
| Cell- and Tissue-Based Therapy | 2 | 2023 | 58 | 0.250 |
Why?
|
| Bone Marrow Cells | 1 | 2007 | 264 | 0.250 |
Why?
|
| T-Lymphocytes, Cytotoxic | 4 | 2014 | 318 | 0.250 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 3 | 2008 | 209 | 0.230 |
Why?
|
| Epitopes | 3 | 2010 | 249 | 0.230 |
Why?
|
| Receptor, Macrophage Colony-Stimulating Factor | 2 | 2015 | 9 | 0.230 |
Why?
|
| Prostatic Neoplasms | 2 | 2021 | 1771 | 0.230 |
Why?
|
| Leukemia, Myeloid | 2 | 2003 | 251 | 0.230 |
Why?
|
| CD40 Ligand | 2 | 2003 | 73 | 0.220 |
Why?
|
| Signal Transduction | 8 | 2022 | 3508 | 0.220 |
Why?
|
| Sirolimus | 1 | 2025 | 174 | 0.220 |
Why?
|
| Tumor Cells, Cultured | 4 | 2012 | 1052 | 0.210 |
Why?
|
| Monitoring, Immunologic | 2 | 2021 | 19 | 0.210 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2025 | 209 | 0.210 |
Why?
|
| B7-1 Antigen | 2 | 2003 | 75 | 0.210 |
Why?
|
| Apoptosis | 7 | 2014 | 1743 | 0.210 |
Why?
|
| Mice, SCID | 5 | 2021 | 265 | 0.210 |
Why?
|
| Membrane Potentials | 2 | 2005 | 436 | 0.210 |
Why?
|
| Mitochondria | 3 | 2005 | 599 | 0.200 |
Why?
|
| Cell Survival | 9 | 2021 | 1008 | 0.200 |
Why?
|
| Hematopoietic Stem Cells | 3 | 2014 | 310 | 0.200 |
Why?
|
| Adenocarcinoma | 1 | 2010 | 1191 | 0.200 |
Why?
|
| CTLA-4 Antigen | 5 | 2015 | 141 | 0.200 |
Why?
|
| T Cell Transcription Factor 1 | 1 | 2022 | 23 | 0.190 |
Why?
|
| MAP Kinase Signaling System | 5 | 2017 | 200 | 0.190 |
Why?
|
| Receptors, CXCR6 | 1 | 2021 | 6 | 0.190 |
Why?
|
| Female | 26 | 2025 | 47893 | 0.180 |
Why?
|
| Indoleamine-Pyrrole 2,3,-Dioxygenase | 1 | 2022 | 60 | 0.180 |
Why?
|
| Interferon Type I | 1 | 2022 | 191 | 0.180 |
Why?
|
| Mitochondria, Liver | 2 | 2000 | 29 | 0.180 |
Why?
|
| Genes, ras | 2 | 2012 | 97 | 0.180 |
Why?
|
| Cytochrome c Group | 2 | 2000 | 83 | 0.180 |
Why?
|
| Porphyrins | 1 | 2021 | 39 | 0.180 |
Why?
|
| Erlotinib Hydrochloride | 1 | 2021 | 88 | 0.180 |
Why?
|
| Quinoxalines | 1 | 2021 | 50 | 0.180 |
Why?
|
| Photosensitizing Agents | 1 | 2021 | 52 | 0.170 |
Why?
|
| Myofibroblasts | 1 | 2021 | 50 | 0.170 |
Why?
|
| Models, Animal | 2 | 2012 | 282 | 0.170 |
Why?
|
| Intracellular Membranes | 1 | 2000 | 117 | 0.170 |
Why?
|
| Histone-Lysine N-Methyltransferase | 1 | 2021 | 163 | 0.160 |
Why?
|
| Cytokines | 5 | 2019 | 843 | 0.160 |
Why?
|
| Proto-Oncogene Proteins c-akt | 4 | 2013 | 364 | 0.160 |
Why?
|
| Membrane Proteins | 4 | 2025 | 1240 | 0.160 |
Why?
|
| Genes, T-Cell Receptor | 1 | 2019 | 10 | 0.160 |
Why?
|
| Wound Healing | 1 | 2021 | 373 | 0.150 |
Why?
|
| Gene Library | 2 | 2018 | 134 | 0.150 |
Why?
|
| Male | 23 | 2025 | 43925 | 0.150 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 3 | 2010 | 373 | 0.150 |
Why?
|
| Cell Engineering | 1 | 2018 | 5 | 0.150 |
Why?
|
| Repressor Proteins | 2 | 2021 | 434 | 0.150 |
Why?
|
| Single-Cell Analysis | 2 | 2017 | 174 | 0.150 |
Why?
|
| Gene Expression | 3 | 2013 | 1312 | 0.140 |
Why?
|
| Immunity | 1 | 2019 | 149 | 0.140 |
Why?
|
| Vancomycin | 1 | 1998 | 73 | 0.140 |
Why?
|
| Gene Expression Profiling | 2 | 2021 | 1477 | 0.140 |
Why?
|
| Neutropenia | 1 | 1998 | 217 | 0.140 |
Why?
|
| Immunotherapy, Active | 2 | 2015 | 15 | 0.140 |
Why?
|
| Neutrophils | 1 | 2019 | 323 | 0.140 |
Why?
|
| Fever | 1 | 1998 | 130 | 0.140 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2019 | 283 | 0.130 |
Why?
|
| Interleukin-4 | 3 | 2007 | 131 | 0.130 |
Why?
|
| Cell Proliferation | 6 | 2019 | 1720 | 0.130 |
Why?
|
| Mutation | 7 | 2015 | 4204 | 0.130 |
Why?
|
| Pyrimidinones | 2 | 2015 | 39 | 0.120 |
Why?
|
| Neoplasm Transplantation | 5 | 2021 | 398 | 0.120 |
Why?
|
| Cell Culture Techniques | 2 | 2021 | 200 | 0.120 |
Why?
|
| Pyridones | 2 | 2015 | 58 | 0.120 |
Why?
|
| Monocytes | 2 | 2009 | 223 | 0.120 |
Why?
|
| Positron-Emission Tomography | 2 | 2014 | 341 | 0.120 |
Why?
|
| Tissue Distribution | 2 | 2019 | 295 | 0.120 |
Why?
|
| MAP Kinase Kinase 1 | 2 | 2012 | 39 | 0.120 |
Why?
|
| fas Receptor | 3 | 2011 | 78 | 0.120 |
Why?
|
| Gene Expression Regulation, Neoplastic | 4 | 2021 | 1310 | 0.120 |
Why?
|
| MAP Kinase Kinase Kinases | 1 | 2015 | 41 | 0.120 |
Why?
|
| Coculture Techniques | 3 | 2021 | 176 | 0.120 |
Why?
|
| Cloning, Molecular | 5 | 2018 | 643 | 0.120 |
Why?
|
| Genes, Transgenic, Suicide | 1 | 2014 | 3 | 0.120 |
Why?
|
| Histocompatibility Antigens Class I | 3 | 2011 | 205 | 0.110 |
Why?
|
| Antibodies, Blocking | 2 | 2011 | 22 | 0.110 |
Why?
|
| Cell Cycle | 5 | 2015 | 515 | 0.110 |
Why?
|
| Adjuvants, Immunologic | 2 | 2006 | 169 | 0.110 |
Why?
|
| Adult | 15 | 2025 | 27532 | 0.110 |
Why?
|
| Kinetics | 2 | 2010 | 1550 | 0.110 |
Why?
|
| Natural Killer T-Cells | 1 | 2013 | 46 | 0.100 |
Why?
|
| NK Cell Lectin-Like Receptor Subfamily A | 1 | 2013 | 3 | 0.100 |
Why?
|
| Carbonic Anhydrase IX | 1 | 2013 | 11 | 0.100 |
Why?
|
| Chemokine CCL1 | 1 | 2013 | 4 | 0.100 |
Why?
|
| Fibrinogen | 1 | 2013 | 51 | 0.100 |
Why?
|
| Histone Deacetylase Inhibitors | 1 | 2014 | 106 | 0.100 |
Why?
|
| Mice, Inbred BALB C | 2 | 2013 | 1108 | 0.100 |
Why?
|
| Mitogen-Activated Protein Kinases | 1 | 2013 | 228 | 0.100 |
Why?
|
| Lectins, C-Type | 1 | 2013 | 87 | 0.100 |
Why?
|
| Jurkat Cells | 4 | 2018 | 81 | 0.100 |
Why?
|
| Cell Separation | 2 | 2010 | 202 | 0.100 |
Why?
|
| Aged | 12 | 2025 | 19943 | 0.100 |
Why?
|
| Anti-Bacterial Agents | 1 | 1998 | 810 | 0.100 |
Why?
|
| Uveal Neoplasms | 1 | 2012 | 11 | 0.100 |
Why?
|
| Xenograft Model Antitumor Assays | 2 | 2013 | 502 | 0.100 |
Why?
|
| Cell Adhesion Molecules | 1 | 2013 | 167 | 0.100 |
Why?
|
| Combined Modality Therapy | 2 | 2015 | 1733 | 0.100 |
Why?
|
| Congresses as Topic | 1 | 2012 | 120 | 0.090 |
Why?
|
| Herpesvirus 1, Human | 1 | 2014 | 245 | 0.090 |
Why?
|
| Th1 Cells | 2 | 2013 | 168 | 0.090 |
Why?
|
| Cell Line | 5 | 2012 | 2505 | 0.090 |
Why?
|
| Fas Ligand Protein | 1 | 2011 | 50 | 0.090 |
Why?
|
| T-Lymphocytes, Helper-Inducer | 2 | 2010 | 139 | 0.090 |
Why?
|
| Models, Biological | 1 | 2019 | 1786 | 0.090 |
Why?
|
| Gene Amplification | 1 | 2012 | 137 | 0.090 |
Why?
|
| Receptors, Cell Surface | 1 | 2013 | 291 | 0.090 |
Why?
|
| Recombinant Proteins | 3 | 2003 | 1016 | 0.090 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 1998 | 923 | 0.090 |
Why?
|
| Middle Aged | 13 | 2025 | 27030 | 0.090 |
Why?
|
| Lab-On-A-Chip Devices | 1 | 2011 | 25 | 0.090 |
Why?
|
| Antibodies | 1 | 2013 | 351 | 0.090 |
Why?
|
| HLA-A Antigens | 1 | 2010 | 40 | 0.090 |
Why?
|
| Ribonucleoside Diphosphate Reductase | 1 | 2010 | 7 | 0.090 |
Why?
|
| T-Lymphocytes, Regulatory | 2 | 2013 | 333 | 0.090 |
Why?
|
| Azacitidine | 1 | 2011 | 148 | 0.090 |
Why?
|
| Antineoplastic Protocols | 1 | 2010 | 9 | 0.090 |
Why?
|
| Monophenol Monooxygenase | 1 | 2010 | 9 | 0.090 |
Why?
|
| Survival Analysis | 2 | 2021 | 1511 | 0.090 |
Why?
|
| Neoplasms, Experimental | 1 | 2012 | 270 | 0.090 |
Why?
|
| Chromosomes, Human, Pair 15 | 2 | 2002 | 66 | 0.090 |
Why?
|
| Tumor Escape | 1 | 2010 | 52 | 0.090 |
Why?
|
| Chemotaxis, Leukocyte | 1 | 2010 | 39 | 0.090 |
Why?
|
| Dacarbazine | 1 | 2010 | 101 | 0.080 |
Why?
|
| Transforming Growth Factor beta | 1 | 2012 | 328 | 0.080 |
Why?
|
| Gene Silencing | 1 | 2010 | 180 | 0.080 |
Why?
|
| Peptide Fragments | 2 | 2014 | 465 | 0.080 |
Why?
|
| Molecular Imaging | 1 | 2010 | 70 | 0.080 |
Why?
|
| Oximes | 3 | 2015 | 17 | 0.080 |
Why?
|
| Genes, Reporter | 1 | 2010 | 276 | 0.080 |
Why?
|
| Histocompatibility Antigens | 1 | 2009 | 38 | 0.080 |
Why?
|
| Cytological Techniques | 1 | 2009 | 31 | 0.080 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 1 | 2010 | 163 | 0.080 |
Why?
|
| Protein Array Analysis | 1 | 2009 | 52 | 0.080 |
Why?
|
| Neoplasm Metastasis | 5 | 2014 | 1071 | 0.080 |
Why?
|
| Transfection | 3 | 2007 | 901 | 0.080 |
Why?
|
| Antibodies, Monoclonal, Humanized | 5 | 2014 | 977 | 0.080 |
Why?
|
| Caspases | 2 | 2000 | 158 | 0.080 |
Why?
|
| Glioma | 1 | 2011 | 303 | 0.080 |
Why?
|
| DNA, Single-Stranded | 1 | 2009 | 93 | 0.080 |
Why?
|
| Imidazoles | 3 | 2015 | 141 | 0.080 |
Why?
|
| Nitrophenols | 1 | 2008 | 12 | 0.080 |
Why?
|
| RNA, Small Interfering | 1 | 2010 | 561 | 0.080 |
Why?
|
| DNA, Complementary | 4 | 2009 | 392 | 0.080 |
Why?
|
| Hepacivirus | 1 | 2009 | 134 | 0.080 |
Why?
|
| Biphenyl Compounds | 1 | 2008 | 61 | 0.070 |
Why?
|
| Immunophenotyping | 2 | 2010 | 222 | 0.070 |
Why?
|
| MicroRNAs | 1 | 2013 | 575 | 0.070 |
Why?
|
| Leukocytes, Mononuclear | 3 | 2014 | 207 | 0.070 |
Why?
|
| Cells, Cultured | 4 | 2018 | 2902 | 0.070 |
Why?
|
| Luciferases | 1 | 2007 | 129 | 0.070 |
Why?
|
| Phosphatidylinositol 3-Kinases | 3 | 2013 | 276 | 0.070 |
Why?
|
| Cytomegalovirus | 1 | 2007 | 85 | 0.070 |
Why?
|
| Molecular Targeted Therapy | 3 | 2015 | 291 | 0.070 |
Why?
|
| Histocompatibility Antigens Class II | 1 | 2007 | 165 | 0.070 |
Why?
|
| Mice, Inbred NOD | 2 | 2018 | 206 | 0.060 |
Why?
|
| HEK293 Cells | 3 | 2013 | 666 | 0.060 |
Why?
|
| Aminoquinolines | 1 | 2006 | 18 | 0.060 |
Why?
|
| Immunohistochemistry | 2 | 2007 | 1807 | 0.060 |
Why?
|
| Carrier Proteins | 2 | 1999 | 680 | 0.060 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2012 | 1091 | 0.060 |
Why?
|
| Retroviridae | 2 | 2018 | 76 | 0.060 |
Why?
|
| Central Nervous System Neoplasms | 1 | 2006 | 90 | 0.060 |
Why?
|
| Phenotype | 4 | 2017 | 2498 | 0.060 |
Why?
|
| Polymerase Chain Reaction | 1 | 2007 | 923 | 0.060 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2015 | 2556 | 0.060 |
Why?
|
| Base Sequence | 4 | 2012 | 2317 | 0.060 |
Why?
|
| Proteome | 2 | 2017 | 149 | 0.060 |
Why?
|
| Lipopolysaccharide Receptors | 1 | 2004 | 23 | 0.060 |
Why?
|
| Transgenes | 3 | 2011 | 184 | 0.060 |
Why?
|
| RNA, Messenger | 2 | 2022 | 2037 | 0.060 |
Why?
|
| Colonic Neoplasms | 1 | 2008 | 583 | 0.050 |
Why?
|
| Promoter Regions, Genetic | 1 | 2007 | 968 | 0.050 |
Why?
|
| Immunologic Memory | 1 | 2025 | 177 | 0.050 |
Why?
|
| Amyloid beta-Peptides | 1 | 2005 | 214 | 0.050 |
Why?
|
| Aged, 80 and over | 5 | 2013 | 6916 | 0.050 |
Why?
|
| Drug Synergism | 2 | 2015 | 312 | 0.050 |
Why?
|
| Neoplasm Staging | 3 | 2014 | 2035 | 0.050 |
Why?
|
| Interleukin-12 | 1 | 2003 | 111 | 0.050 |
Why?
|
| Caspase 3 | 2 | 2000 | 164 | 0.050 |
Why?
|
| Lymphocyte Culture Test, Mixed | 1 | 2002 | 73 | 0.050 |
Why?
|
| Antigens, CD34 | 2 | 2014 | 161 | 0.050 |
Why?
|
| Immunity, Cellular | 2 | 2013 | 182 | 0.050 |
Why?
|
| Receptor, Platelet-Derived Growth Factor beta | 2 | 2013 | 26 | 0.050 |
Why?
|
| eIF-2 Kinase | 1 | 2022 | 47 | 0.050 |
Why?
|
| Lymphocyte Count | 2 | 2014 | 100 | 0.050 |
Why?
|
| Unfolded Protein Response | 1 | 2022 | 46 | 0.050 |
Why?
|
| Analysis of Variance | 1 | 2004 | 901 | 0.050 |
Why?
|
| Drug Screening Assays, Antitumor | 2 | 2015 | 83 | 0.050 |
Why?
|
| Endoplasmic Reticulum Stress | 1 | 2022 | 86 | 0.050 |
Why?
|
| Granzymes | 1 | 2022 | 94 | 0.050 |
Why?
|
| Gene Expression Regulation | 1 | 2010 | 2004 | 0.050 |
Why?
|
| NAD | 1 | 2022 | 92 | 0.050 |
Why?
|
| Testis | 1 | 2002 | 152 | 0.050 |
Why?
|
| Tryptophan | 1 | 2022 | 103 | 0.050 |
Why?
|
| Inhibitory Concentration 50 | 2 | 2012 | 66 | 0.050 |
Why?
|
| Treatment Outcome | 4 | 2014 | 8740 | 0.050 |
Why?
|
| NF-kappa B | 2 | 2017 | 470 | 0.050 |
Why?
|
| Survival Rate | 2 | 2021 | 1927 | 0.050 |
Why?
|
| Biophysics | 1 | 2021 | 153 | 0.040 |
Why?
|
| Cell Division | 1 | 2002 | 701 | 0.040 |
Why?
|
| Stereoisomerism | 1 | 2021 | 103 | 0.040 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 2 | 2012 | 98 | 0.040 |
Why?
|
| Porins | 1 | 2000 | 21 | 0.040 |
Why?
|
| Alzheimer Disease | 1 | 2005 | 518 | 0.040 |
Why?
|
| Rats | 3 | 2005 | 4067 | 0.040 |
Why?
|
| Atractyloside | 1 | 2000 | 2 | 0.040 |
Why?
|
| Ion Transport | 1 | 2000 | 86 | 0.040 |
Why?
|
| Protoporphyrins | 1 | 2000 | 19 | 0.040 |
Why?
|
| Caspase 8 | 1 | 2000 | 35 | 0.040 |
Why?
|
| Phosphatidylinositols | 1 | 2000 | 21 | 0.040 |
Why?
|
| Thapsigargin | 1 | 2000 | 55 | 0.040 |
Why?
|
| Acute Disease | 1 | 2002 | 856 | 0.040 |
Why?
|
| Caspase 9 | 1 | 2000 | 49 | 0.040 |
Why?
|
| Staurosporine | 1 | 2000 | 33 | 0.040 |
Why?
|
| bcl-2-Associated X Protein | 1 | 2000 | 55 | 0.040 |
Why?
|
| Aging | 1 | 2005 | 738 | 0.040 |
Why?
|
| Photochemotherapy | 1 | 2021 | 101 | 0.040 |
Why?
|
| Methylation | 1 | 2021 | 280 | 0.040 |
Why?
|
| Structure-Activity Relationship | 1 | 2021 | 432 | 0.040 |
Why?
|
| Macrophages | 2 | 2015 | 599 | 0.040 |
Why?
|
| Extracellular Matrix | 1 | 2021 | 250 | 0.040 |
Why?
|
| Sequence Analysis, DNA | 2 | 2014 | 874 | 0.040 |
Why?
|
| Granulocytes | 1 | 2019 | 38 | 0.040 |
Why?
|
| Muromonab-CD3 | 1 | 2019 | 70 | 0.040 |
Why?
|
| Sequence Analysis, RNA | 1 | 2021 | 247 | 0.040 |
Why?
|
| Complement C3 | 1 | 2019 | 58 | 0.040 |
Why?
|
| Myeloid-Derived Suppressor Cells | 1 | 2019 | 27 | 0.040 |
Why?
|
| Vaccination | 2 | 2014 | 285 | 0.040 |
Why?
|
| CD28 Antigens | 1 | 2019 | 93 | 0.040 |
Why?
|
| Histones | 1 | 2021 | 351 | 0.040 |
Why?
|
| Up-Regulation | 2 | 2011 | 731 | 0.040 |
Why?
|
| Drug Resistance, Microbial | 1 | 1998 | 75 | 0.040 |
Why?
|
| Cysteine Endopeptidases | 1 | 1998 | 86 | 0.040 |
Why?
|
| Smoking | 1 | 2002 | 640 | 0.040 |
Why?
|
| Frozen Sections | 1 | 2018 | 49 | 0.040 |
Why?
|
| Gram-Positive Bacterial Infections | 1 | 1998 | 51 | 0.040 |
Why?
|
| Markov Chains | 1 | 2017 | 131 | 0.030 |
Why?
|
| Transplantation, Autologous | 1 | 1998 | 355 | 0.030 |
Why?
|
| Mice, Knockout | 1 | 2021 | 2087 | 0.030 |
Why?
|
| Neurons | 1 | 2005 | 1596 | 0.030 |
Why?
|
| Epigenesis, Genetic | 1 | 2021 | 538 | 0.030 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2000 | 680 | 0.030 |
Why?
|
| Blotting, Western | 2 | 2012 | 795 | 0.030 |
Why?
|
| DNA Methylation | 1 | 2021 | 677 | 0.030 |
Why?
|
| Proteomics | 1 | 2017 | 246 | 0.030 |
Why?
|
| Membrane Glycoproteins | 2 | 2009 | 438 | 0.030 |
Why?
|
| Cost-Benefit Analysis | 1 | 1998 | 490 | 0.030 |
Why?
|
| Adaptation, Physiological | 1 | 2017 | 322 | 0.030 |
Why?
|
| Aminopyridines | 1 | 2015 | 45 | 0.030 |
Why?
|
| Major Histocompatibility Complex | 1 | 2015 | 85 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2010 | 1939 | 0.030 |
Why?
|
| Pyrroles | 1 | 2015 | 171 | 0.030 |
Why?
|
| Complementarity Determining Regions | 1 | 2014 | 25 | 0.030 |
Why?
|
| Substrate Specificity | 2 | 2009 | 362 | 0.030 |
Why?
|
| Hydroxamic Acids | 1 | 2014 | 50 | 0.030 |
Why?
|
| Clonal Evolution | 1 | 2013 | 16 | 0.030 |
Why?
|
| Receptors, Antigen, T-Cell, alpha-beta | 1 | 2014 | 100 | 0.030 |
Why?
|
| Head and Neck Neoplasms | 1 | 2021 | 1076 | 0.030 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2015 | 183 | 0.030 |
Why?
|
| Recombinant Fusion Proteins | 2 | 2008 | 559 | 0.030 |
Why?
|
| Tumor Necrosis Factor Receptor Superfamily, Member 9 | 1 | 2013 | 17 | 0.030 |
Why?
|
| Receptors, CCR2 | 1 | 2013 | 33 | 0.030 |
Why?
|
| Chemokine CCL2 | 1 | 2013 | 48 | 0.030 |
Why?
|
| Cluster Analysis | 1 | 2014 | 376 | 0.030 |
Why?
|
| Prognosis | 1 | 2021 | 3872 | 0.030 |
Why?
|
| ras Proteins | 1 | 2013 | 133 | 0.030 |
Why?
|
| PTEN Phosphohydrolase | 1 | 2013 | 142 | 0.030 |
Why?
|
| Th2 Cells | 1 | 2013 | 148 | 0.030 |
Why?
|
| Phosphoproteins | 1 | 2014 | 266 | 0.020 |
Why?
|
| Radioactive Tracers | 1 | 2012 | 6 | 0.020 |
Why?
|
| DNA Damage | 1 | 2014 | 381 | 0.020 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 1 | 2012 | 122 | 0.020 |
Why?
|
| Microchip Analytical Procedures | 1 | 2011 | 3 | 0.020 |
Why?
|
| Stem Cell Transplantation | 1 | 2012 | 190 | 0.020 |
Why?
|
| Exome | 1 | 2012 | 134 | 0.020 |
Why?
|
| Mutation, Missense | 1 | 2013 | 288 | 0.020 |
Why?
|
| Benzimidazoles | 1 | 2012 | 109 | 0.020 |
Why?
|
| Down-Regulation | 1 | 2013 | 523 | 0.020 |
Why?
|
| Neoplastic Stem Cells | 1 | 2012 | 167 | 0.020 |
Why?
|
| K562 Cells | 1 | 2010 | 47 | 0.020 |
Why?
|
| DNA Copy Number Variations | 1 | 2012 | 184 | 0.020 |
Why?
|
| ZAP-70 Protein-Tyrosine Kinase | 1 | 2010 | 18 | 0.020 |
Why?
|
| Osmolar Concentration | 1 | 2010 | 181 | 0.020 |
Why?
|
| Thymus Gland | 1 | 2011 | 201 | 0.020 |
Why?
|
| Cell Death | 1 | 2011 | 261 | 0.020 |
Why?
|
| S Phase | 1 | 2010 | 63 | 0.020 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2010 | 109 | 0.020 |
Why?
|
| G1 Phase | 1 | 2010 | 67 | 0.020 |
Why?
|
| Precision Medicine | 1 | 2015 | 425 | 0.020 |
Why?
|
| Computational Biology | 1 | 2014 | 566 | 0.020 |
Why?
|
| Exons | 1 | 2012 | 453 | 0.020 |
Why?
|
| Viral Structural Proteins | 1 | 2009 | 17 | 0.020 |
Why?
|
| B7-2 Antigen | 1 | 2009 | 40 | 0.020 |
Why?
|
| Antineoplastic Agents, Alkylating | 1 | 2010 | 134 | 0.020 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2002 | 891 | 0.020 |
Why?
|
| Cell Communication | 1 | 2010 | 205 | 0.020 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2010 | 203 | 0.020 |
Why?
|
| Lipopolysaccharides | 1 | 2011 | 301 | 0.020 |
Why?
|
| Glass | 1 | 2009 | 15 | 0.020 |
Why?
|
| Streptavidin | 1 | 2009 | 14 | 0.020 |
Why?
|
| DNA Restriction Enzymes | 1 | 2009 | 97 | 0.020 |
Why?
|
| Immobilized Proteins | 1 | 2009 | 14 | 0.020 |
Why?
|
| DNA Primers | 2 | 2002 | 542 | 0.020 |
Why?
|
| Lung Neoplasms | 1 | 2002 | 2394 | 0.020 |
Why?
|
| Viral Nonstructural Proteins | 1 | 2009 | 42 | 0.020 |
Why?
|
| Intracellular Space | 1 | 2009 | 38 | 0.020 |
Why?
|
| Nucleic Acid Hybridization | 1 | 2009 | 241 | 0.020 |
Why?
|
| Protein Structure, Quaternary | 1 | 2009 | 101 | 0.020 |
Why?
|
| Enzyme Activation | 1 | 2010 | 698 | 0.020 |
Why?
|
| Stem Cells | 1 | 2011 | 383 | 0.020 |
Why?
|
| Immunoglobulins | 1 | 2009 | 139 | 0.020 |
Why?
|
| Amino Acid Substitution | 1 | 2010 | 336 | 0.020 |
Why?
|
| Receptors, Death Domain | 1 | 2008 | 3 | 0.020 |
Why?
|
| Intramolecular Oxidoreductases | 1 | 2008 | 9 | 0.020 |
Why?
|
| Killer Cells, Lymphokine-Activated | 1 | 2008 | 27 | 0.020 |
Why?
|
| TNF-Related Apoptosis-Inducing Ligand | 1 | 2008 | 26 | 0.020 |
Why?
|
| In Vitro Techniques | 1 | 2010 | 997 | 0.020 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2010 | 698 | 0.020 |
Why?
|
| Interleukin-17 | 1 | 2009 | 107 | 0.020 |
Why?
|
| Protein Multimerization | 1 | 2009 | 184 | 0.020 |
Why?
|
| Listeria monocytogenes | 1 | 2008 | 94 | 0.020 |
Why?
|
| Autoimmunity | 1 | 2009 | 175 | 0.020 |
Why?
|
| Microtubule-Associated Proteins | 2 | 1999 | 185 | 0.020 |
Why?
|
| Young Adult | 2 | 2010 | 6624 | 0.020 |
Why?
|
| Chromosome Mapping | 2 | 2002 | 1076 | 0.020 |
Why?
|
| Phosphorylation | 1 | 2010 | 1142 | 0.020 |
Why?
|
| Clinical Trials as Topic | 1 | 2012 | 1150 | 0.020 |
Why?
|
| Biopsy | 1 | 2011 | 1194 | 0.020 |
Why?
|
| Virus Internalization | 1 | 2007 | 42 | 0.020 |
Why?
|
| Genetic Variation | 1 | 2014 | 1392 | 0.020 |
Why?
|
| Protein Binding | 1 | 2010 | 1513 | 0.020 |
Why?
|
| Piperazines | 1 | 2008 | 288 | 0.020 |
Why?
|
| Models, Genetic | 1 | 2011 | 967 | 0.020 |
Why?
|
| Calcium | 2 | 2001 | 1183 | 0.020 |
Why?
|
| Diagnostic Imaging | 1 | 2010 | 456 | 0.020 |
Why?
|
| gp100 Melanoma Antigen | 1 | 2006 | 12 | 0.020 |
Why?
|
| Spleen | 1 | 2007 | 435 | 0.020 |
Why?
|
| Brain Neoplasms | 1 | 2011 | 800 | 0.020 |
Why?
|
| Neurotoxins | 1 | 2005 | 47 | 0.010 |
Why?
|
| PC12 Cells | 1 | 2005 | 110 | 0.010 |
Why?
|
| Mice, Nude | 1 | 2007 | 828 | 0.010 |
Why?
|
| Genome, Human | 1 | 2010 | 799 | 0.010 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2008 | 709 | 0.010 |
Why?
|
| Biomarkers, Tumor | 1 | 2012 | 1576 | 0.010 |
Why?
|
| Retrospective Studies | 1 | 1998 | 9703 | 0.010 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2014 | 2680 | 0.010 |
Why?
|
| Drug Combinations | 1 | 2003 | 206 | 0.010 |
Why?
|
| Reproducibility of Results | 1 | 2009 | 2794 | 0.010 |
Why?
|
| Sensitivity and Specificity | 1 | 2007 | 2009 | 0.010 |
Why?
|
| Liver | 1 | 2007 | 1228 | 0.010 |
Why?
|
| Electrophoresis, Gel, Two-Dimensional | 1 | 2001 | 27 | 0.010 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2006 | 608 | 0.010 |
Why?
|
| Organ Specificity | 1 | 2002 | 283 | 0.010 |
Why?
|
| Histidine | 1 | 2001 | 75 | 0.010 |
Why?
|
| Voltage-Dependent Anion Channels | 1 | 2000 | 3 | 0.010 |
Why?
|
| bcl-X Protein | 1 | 2000 | 56 | 0.010 |
Why?
|
| 3T3 Cells | 1 | 2000 | 98 | 0.010 |
Why?
|
| Liposomes | 1 | 2000 | 94 | 0.010 |
Why?
|
| Chelating Agents | 1 | 2000 | 68 | 0.010 |
Why?
|
| HeLa Cells | 1 | 2000 | 514 | 0.010 |
Why?
|
| HL-60 Cells | 1 | 1999 | 25 | 0.010 |
Why?
|
| Species Specificity | 1 | 2000 | 692 | 0.010 |
Why?
|
| Blotting, Northern | 1 | 1999 | 258 | 0.010 |
Why?
|
| Protein Structure, Tertiary | 1 | 2000 | 741 | 0.010 |
Why?
|
| Open Reading Frames | 1 | 1999 | 120 | 0.010 |
Why?
|
| Hydrolysis | 1 | 1998 | 144 | 0.010 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 1999 | 358 | 0.010 |
Why?
|
| Cell Movement | 1 | 2001 | 797 | 0.010 |
Why?
|
| Actins | 1 | 2000 | 470 | 0.010 |
Why?
|
| Protein Biosynthesis | 1 | 1999 | 383 | 0.010 |
Why?
|
| Saccharomyces cerevisiae | 1 | 1998 | 455 | 0.010 |
Why?
|
| Transcription, Genetic | 1 | 1999 | 1163 | 0.010 |
Why?
|
| Time Factors | 1 | 2001 | 5430 | 0.010 |
Why?
|